HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions.
HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions.
复制标题
HIV-1 gp41 靶向融合抑制肽增强 gp120 靶向蛋白介导的 HIV-1 病毒颗粒失活
DOI:
10.1038/emi.2017.46
复制
发表时间:
2017-06-21
影响因子:
13.2
通讯作者:
Jiang S
中科院分区:
文献类型:
--
作者:
Qi Q;Wang Q;Chen W;Du L;Dimitrov DS;Lu L;Jiang S
Protein- or peptide-based viral inactivators are being developed as novel antiviral drugs with improved efficacy, pharmacokinetics and toxicity profiles because they actively inactivate cell-free human immunodeficiency virus type 1 (HIV-1) virions before attachment to host cells. By contrast, most clinically used antiviral drugs must penetrate host cells to inhibit viral replication. In this study, we pre-treated HIV-1 particles with a gp120-targeting bispecific multivalent protein, 2Dm2m or 4Dm2m, in the presence or absence of the gp41-targeting HIV-1 fusion inhibitory peptides enfuvirtide (T20), T2635, or sifuvirtide (SFT). HIV-1 virions were separated from the inhibitors using PEG-6000, followed by testing of the residual infectivity of the HIV-1 virions. 2Dm2m and 4Dm2m exhibited significant inactivation activity against all HIV-1 strains tested with EC50 values at the low nanomolar level, whereas none of the gp41-targeting peptides showed inactivation activity at concentrations up to 250 nM. Notably, these three peptides significantly enhanced protein-mediated inactivation against cell-free HIV-1 virions, including HIV-1 laboratory-adapted and primary HIV-1 strains, as well as those resistant to T20 or T2635 and virions released from reactivated latently HIV-1-infected cells. These results indicate that the gp120-targeting bispecific multivalent proteins 2Dm2m and 4Dm2m have potential for further development as HIV-1 inactivator-based antiviral drugs for use in the clinic, either alone or in combination with a gp41-targeting HIV-1 fusion inhibitor such as T20, to treat patients with HIV-1 infection and AIDS.
登录
查看更多内容
影响因子:
3.3
作者:
Lagenaur LA;Villarroel VA;Bundoc V;Dey B;Berger EA
通讯作者:
Berger EA
影响因子:
5.4
作者:
Dey, B;Del Castillo, CS;Berger, EA
通讯作者:
Berger, EA
影响因子:
5.2
作者:
Chong, Huihui;Yao, Xue;He, Yuxian
通讯作者:
He, Yuxian
影响因子:
5.4
作者:
Chen, Weizao;Feng, Yang;Dimitrov, Dimiter S.
通讯作者:
Dimitrov, Dimiter S.
影响因子:
2.9
作者:
EDELHOCH, H
通讯作者:
EDELHOCH, H